For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a
platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …

For more than 10 years, dual antiplatelet therapy with aspirin and clopidogrel has remained
the cornerstone of treatment for patients with acute coronary syndrome (ACS). The novel …

Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …

Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …

In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …

Background Clopidogrel requires transformation into an active metabolite by cytochrome P-
450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are …

Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Thrombophilia is considered as a condition predisposing to the development of thrombosis.
Arterial thrombosis usually occurs after the erosion or rupture of an atherosclerotic plaque …

Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

Most patients with atrial fibrillation (AF) and risk factors for stroke require oral anticoagulation
(OAC) to decrease the risk of stroke or systemic embolism. This is now best achieved with …